FDA Delays Decisions on Lilly's Obesity Pill and Other Fast-Track Drug Reviews

FDA extends review timelines for Eli Lilly's obesity pill Orforglipron and three other priority voucher drugs, despite promises of accelerated 1-2 month reviews under new program.